Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant staphylococcus aureus bacteremia

Pharmacotherapy

Volumn 33, Issue 1, 2013, Pages 3-10

  Kullar, Ravina ^a   Davis, Susan L ^a,b   Kaye, Keith S ^a   Levine, Donald P ^c   Pogue, Jason M ^d   Rybak, Michael J ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SINAI GRACE HOSPITAL   (United States)

Author keywords

Bacteremia; Daptomycin; Elevated vancomycin MICs; Methicillin resistant staphylococcus aureus; MRSA; Mrsab pathway

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG COST; DRUG SUBSTITUTION; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QUASI EXPERIMENTAL STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84875437888     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1220     Document Type: Article

References (35)

1. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36 (11):1418-23.
2. National Nosocomial Infections Surveillance (NNIS). System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32(8):470-85.
3. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36(5):592-8.
4. Shorr AF. Epidemiology and economic impact of meticillinresistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics 2007;25(9):751-68.
5. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36(1):53-9.
6. Whitby M, McLaws ML, Berry G. Risk of death from methicillin- resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001;175(5):264-7.
7. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005;52(2):113-22.
8. Fowler VG Jr, Miro JM, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005;293 (24):3012-21.
9. Hill EE, Herijgers P, Herregods MC, Peetermans WE. Evolving trends in infective endocarditis. Clin Microbiol Infect 2006;12(1):5-12.
10. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1-12.
11. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011;52(8):975-81.
12. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46(2):193-200.
13. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis 2011;52(8):969-74.
14. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillinresistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52(9):3315-20.
15. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42(6):2398-402.
16. Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012;54(6):755-71.
17. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355 (7):653-65.
18. Cubist Pharmaceuticals, Inc. Product information: Cubicin®, daptomycin for injection. Lexington, MA; 2003.
19. Kullar R, Leonard SN, Davis SL, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 2011;31(5):441-8.
20. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66(1):82-98.
21. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically; approved standard, 8th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
22. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008;46(9):2950-4.
23. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007;45(2):329-32.
24. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005;43(10):5026-33.
25. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29(5):1128-32.
26. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44(2):159-77.
27. Hsu DI, Hidayat LK, Quist R, et al. Comparison of methodspecific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillinresistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008;32(5):378-85.
28. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52(3):285-92.
29. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012;54 (1):51-8.
30. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011;66(10):2386-92.
31. Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007;167 (17):1861-7.
32. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006;50 (4):1581-5.
33. Rose WE, Leonard SN, Sakoulas G, et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52 (3):831-6.
34. Harris AD, Lautenbach E, Perencevich E. A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. Clin Infect Dis 2005;41(1): 77-82.
35. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasiexperimental studies in infectious diseases. Clin Infect Dis 2004;38(11):1586-91.